Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Marksans Pharma Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 486 | 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 | 720 | 754 | 856 |
| Expenses + | 376 | 398 | 417 | 453 | 450 | 462 | 495 | 543 | 582 | 520 | 576 | 594 | 661 |
| Operating Profit | 110 | 102 | 114 | 133 | 110 | 128 | 147 | 139 | 127 | 100 | 144 | 161 | 195 |
| OPM % | 23% | 20% | 21% | 23% | 20% | 22% | 23% | 20% | 18% | 16% | 20% | 21% | 23% |
| Other Income + | 11 | 10 | 19 | 5 | 17 | 15 | -0 | 28 | 15 | 6 | 22 | 20 | 35 |
| Interest | 2 | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 |
| Depreciation | 14 | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 | 27 | 24 | 24 |
| Profit before tax | 104 | 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 | 133 | 151 | 200 |
| Tax % | 21% | 27% | 26% | 26% | 23% | 26% | 22% | 27% | 22% | 24% | 26% | 25% | 25% |
| Net Profit + | 83 | 70 | 84 | 83 | 78 | 89 | 98 | 105 | 91 | 58 | 99 | 114 | 149 |
| EPS in Rs | 1.81 | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 |
Financials of Marksans Pharma Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,951 |
| Expenses + | 612 | 757 | 722 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 2,094 | 2,350 |
| Operating Profit | 185 | 136 | 45 | 78 | 132 | 192 | 340 | 259 | 340 | 459 | 529 | 601 |
| OPM % | 23% | 15% | 6% | 9% | 13% | 17% | 25% | 17% | 18% | 21% | 20% | 20% |
| Other Income + | 3 | 9 | 7 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 70 | 83 |
| Interest | 16 | 10 | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 12 | 24 |
| Depreciation | 16 | 28 | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 99 |
| Profit before tax | 156 | 107 | 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 561 |
| Tax % | 28% | 23% | 24% | 28% | 23% | 23% | 21% | 25% | 21% | 26% | 24% | 25% |
| Net Profit + | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 420 |
| EPS in Rs | 2.67 | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 5.88 | 6.92 | 8.40 | 9.22 |
| Dividend Payout % | 4% | 21% | 23% | 6% | 3% | 3% | 4% | 6% | 9% | 9% | 10% | 0% |
Financials of Marksans Pharma Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 | 45 |
| Reserves | 326 | 401 | 392 | 430 | 502 | 595 | 846 | 1,161 | 1,700 | 2,020 | 2,422 | 2,978 |
| Borrowings + | 101 | 100 | 110 | 118 | 100 | 30 | 34 | 111 | 123 | 244 | 322 | 343 |
| Other Liabilities + | 207 | 180 | 209 | 142 | 160 | 236 | 307 | 323 | 322 | 372 | 451 | 494 |
| Total Liabilities | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,861 |
| Fixed Assets + | 166 | 270 | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 | 1,088 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 27 | 15 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 | 0 |
| Other Assets + | 510 | 452 | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,694 | 1,869 | 2,230 | 2,758 |
| Total Assets | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,861 |
Financials of Marksans Pharma Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 155 | 31 | 14 | 50 | 27 | 233 | 179 | 99 | 237 | 230 | 207 | 458 |
| Cash from Investing Activity + | -33 | -123 | -21 | -39 | -13 | -60 | -45 | -84 | -259 | -141 | -49 | -248 |
| Cash from Financing Activity + | 17 | -58 | -3 | 3 | -21 | -114 | -15 | 80 | 198 | -69 | -65 | -71 |
| Net Cash Flow | 138 | -150 | -10 | 15 | -7 | 60 | 118 | 94 | 176 | 21 | 93 | 139 |
| Free Cash Flow | 118 | -101 | -14 | 11 | 14 | 174 | 133 | 53 | 184 | 22 | 35 | 329 |
| CFO/OP | 108% | 43% | 31% | 73% | 41% | 134% | 67% | 66% | 88% | 77% | 63% | 100% |
Financials of Marksans Pharma Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 84 | 89 | 118 | 71 | 64 | 78 | 72 | 97 | 82 | 76 | 75 | 80 |
| Inventory Days | 107 | 120 | 151 | 152 | 215 | 155 | 248 | 216 | 192 | 217 | 270 | 278 |
| Days Payable | 88 | 85 | 129 | 54 | 78 | 71 | 103 | 102 | 91 | 94 | 98 | 96 |
| Cash Conversion Cycle | 103 | 124 | 140 | 169 | 202 | 163 | 217 | 211 | 183 | 199 | 247 | 261 |
| Working Capital Days | 17 | 59 | 77 | 70 | 97 | 87 | 104 | 121 | 122 | 129 | 142 | 149 |
| ROCE % | 44% | 23% | 4% | 10% | 18% | 25% | 38% | 23% | 22% | 21% | 20% | 19% |